Understanding the Market | 3D MEDICINES rises over 10% as the first patient administration of its self-developed new generation of precision nuclear medicine is completed, with huge potential in the nuclear medicine market

3D MEDICINES rose over 10%, as of the time of writing, up 13.96%, priced at HKD 9.06, with a trading volume of HKD 17.5877 million. In terms of news, 3D MEDICINES recently announced that the first patient has been dosed in the IIT study of its self-developed nuclear medicine platform's first radiolabeled drug conjugate (RDC) 177Lu-PSMA-3D1015 injection. This study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). According to data from MEDraysintell, the global nuclear medicine market is expected to reach nearly USD 39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection is expected to become a nuclear medicine product with "best-in-class" potential, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide and advancing China's nuclear medicine R&D to an internationally leading level